Oral dosing of GLP-1 compounds

Patent metadata

Field	Value
Publication number	US-12514822-B2
Application number	US-202519192233-A
Country	US
Kind code	B2
Filing date	Apr 28, 2025
Priority date	May 2, 2013
Publication date	Jan 6, 2026
Grant date	Jan 6, 2026

Abstract

The present invention relates to improved uses of glucagon-like peptide 1 (GLP-1) peptides in oral therapy.

First claim

The invention claimed is:

1 . A method for treating type 2 diabetes in a subject in need of such treatment, the method comprising:
orally administering to the subject a composition comprising N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37) (semaglutide) and sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC); wherein the composition comprises 0.5-50 mg of the semaglutide; and wherein the composition is administered such that the ratio between the plasma half-life in days in humans of the semaglutide and the dosing interval in days of the composition is more than 2:1.

2 . The method according to claim 1 , wherein the composition comprises 100 mg of the SNAC.

3 . The method according to claim 1 , wherein the composition comprises 300 mg of the SNAC.

4 . The method according to claim 1 , wherein the composition is in the form of a tablet.

5 . The method according to claim 1 , wherein the semaglutide is the only GLP-1 peptide in the composition.

6 . The method according to claim 5 , wherein the composition comprises 100 mg of the SNAC.

7 . The method according to claim 5 , wherein the composition comprises 300 mg of the SNAC.

8 . The method according to claim 6 or 7 , wherein the composition is in the form of a tablet.

9 . The method according to claim 1 , wherein the subject suffers from obesity.

10 . The composition according to claim 1 , wherein the amount of SNAC is 50-90% (w/w) of the composition.

Assignees

• Novo Nordisk As

Inventors

• Nielsen Flemming S
• Sauerberg Per

Classifications

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K31/166

  having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title